The immune responsiveness in hepatitis C virus infected patients: Effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells

Luigi Amati, R. Cozzolongo, O. G. Manghisi, R. Cuppone, N. M. Pellegrino, D. Caccavo, E. Jirillo

Research output: Contribution to journalArticle

Abstract

Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α/ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand, and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.

Original languageEnglish
Pages (from-to)2093-2100
Number of pages8
JournalCurrent Pharmaceutical Design
Volume10
Issue number17
DOIs
Publication statusPublished - 2004

Keywords

  • B lymphocytes
  • Endotoxins
  • Hepatitis C virus
  • Interferon-α
  • Ribavirin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'The immune responsiveness in hepatitis C virus infected patients: Effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells'. Together they form a unique fingerprint.

  • Cite this